American Society of Hirudotherapy

Heparin-induced Thrombocytopenia Presenting With Deep Venous Thrombosis and Pulmonary Embolism Successfully Treated With Rivaroxaban

Research article published in Journal of cardiovascular pharmacology (2016)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportDrug DevelopmentSamos M et al. · Journal of cardiovascular pharmacology, 2016

Abstract

Heparin-induced thrombocytopenia (HIT) is a life or limb-threatening thrombotic thrombocytopenia. HIT is traditionally treated with factor-IIa inhibitors such as bivalirudin, lepirudin, or argatroban. However, these agents usually require parenteral administration and are not generally available in all countries. Recently, several experiences with novel oral anticoagulants (NOACs) administration to treat HIT had been reported. NOACs generally offer advantages such as consistent and predictable anticoagulation, oral administration with good patient compliance, and a good safety profile. We report a case of HIT with severe thrombotic complications successfully treated with rivaroxaban and discuss the current knowledge about the use of NOACs for the treatment of this potentially fatal thrombocytopenia.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal ArticleReview
Indexed MeSH termsAnticoagulantsDiagnosis, DifferentialFactor Xa InhibitorsFemaleHeparinHumansMiddle AgedPulmonary EmbolismRivaroxabanThrombocytopeniaTreatment OutcomeVenous Thrombosis

Summary

Heparin-induced Thrombocytopenia Presenting With Deep Venous Thrombosis and Pulmonary Embolism Successfully Treated With Rivaroxaban.

Why This Matters for Hirudotherapy

This case report and review describes a patient with heparin-induced thrombocytopenia (HIT) presenting with severe thrombotic complications who was successfully treated with the oral factor Xa inhibitor rivaroxaban, and discusses current knowledge about novel oral anticoagulants for HIT. The review notes that HIT has traditionally been treated with parenteral direct thrombin inhibitors such as bivalirudin, lepirudin, or argatroban, situating hirudin-class agents within the HIT treatment landscape. The ASH relevance is indirect: lepirudin is a recombinant hirudin derived from medicinal leech principles, and the article contextualizes such agents. However, the primary intervention was rivaroxaban, not a hirudin-based therapy, and the abstract does not provide patient demographics or specify the thrombotic complications; the article does not involve leech therapy or leech secretome preparations directly.

Citation

Heparin-induced Thrombocytopenia Presenting With Deep Venous Thrombosis and Pulmonary Embolism Successfully Treated With Rivaroxaban

Samos M et al. · Journal of cardiovascular pharmacology, 2016

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.